C. Lance Cowey
Texas Oncology(US)The US Oncology Network(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Renal cell carcinoma treatment, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,641 cited
- → VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy(2009)165 cited
- → A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma(2019)73 cited
- → Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma(2019)71 cited
- → Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab(2010)71 cited
- → Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting.(2019)13 cited
- Molecularly targeted agents for renal cell carcinoma: the next generation.(2010)
- → 799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data(2020)7 cited
- → A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma(2016)7 cited
- → Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial(2021)5 cited